Dashboard
Manage Tickers

MBRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

moleculin-biotech-secures-canadian-patent-titled-preparation-of-preliposomal-annamycin-lyophilizate
Moleculin Biotech Secures Canadian Patent ...
09/25/2025 12:40:12

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company wit...

moleculin-biotech-files-prospectus-for-resale-from-time-to-time-by-selling-stockholders-of-up-to-649m-shares-of-common-stock
Moleculin Biotech Files Prospectus For Res...
09/19/2025 21:21:15

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/18/2025 21:06:10

hc-wainwright--co-reiterates-buy-on-moleculin-biotech-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Mole...
09/10/2025 10:52:14

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.

moleculin-biotech-announces-its-phase-2b3-miracle-trial-for-annarac-in-relapsed-or-refractory-acute-myeloid-leukemia-is-progressing-with-active-sites-and-ongoing-patient-recruitment-across-the-us-europe-and-the-middle-east
Moleculin Biotech Announces Its Phase 2B/3...
09/09/2025 12:48:45

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company wit...

moleculin-biotech-opens-spain-site-enrolls-first-rr-aml-patients-in-phase-2b3-miracle-trial-on-track-for-45-subjects-in-q4-2025
Moleculin Biotech Opens Spain Site, Enroll...
09/08/2025 12:41:48

Spain site opens with two R/R AML subjects enrolled; One treatedOn track to recruit 45 subjects in 4Q25 for initial data unblin...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/28/2025 17:06:35

nasdaq-surges-100-points-dollar-general-earnings-beat-views
Nasdaq Surges 100 Points; Dollar General E...
08/28/2025 16:54:43

reported-earlier-moleculin-biotech-raises-6m-from-immediate-exercise-of-162m-warrants-at-037share-issues-649m-new-warrants-at-055share
Reported Earlier: Moleculin Biotech Raises...
08/28/2025 16:51:01

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with...

us-stocks-mixed-nvidia-posts-upbeat-earnings
US Stocks Mixed; Nvidia Posts Upbeat Earnings
08/28/2025 14:27:31

hc-wainwright--co-reiterates-buy-on-moleculin-biotech-maintains-4-price-target
HC Wainwright & Co. Reiterates Buy on Mole...
08/27/2025 15:43:38

HC Wainwright & Co. analyst Sara Nik reiterates Moleculin Biotech (NASDAQ:MBRX) with a Buy and maintains $4 price target.

moleculin-biotech-completes-phase-1b2-clinical-trial-evaluating-annamycin-in-combination-with-cytarabine-for-acute-myeloid-leukemia
Moleculin Biotech Completes Phase 1B/2 Cli...
08/27/2025 12:48:14

Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8)Median OS of 2nd Line efficacy evaluable po...

moleculin-biotech-q2-eps-049-misses-042-estimate
Moleculin Biotech Q2 EPS $(0.49) Misses $(...
08/12/2025 21:57:24

Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $...

moleculin-highlights-preclinical-data-for-annamycin-in-liver-cancers-reinforcing-late-stage-aml-development-and-broad-oncology-potential
Moleculin Highlights Preclinical Data For ...
08/06/2025 12:45:15

Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology in...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 21:07:05

moleculin-receives-notice-of-intent-to-grant-european-patent-titled-preparation-of-preliposomal-annamycin-lyophilizate
Moleculin Receives Notice Of Intent To Gra...
07/30/2025 12:36:10

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 21:06:19

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 17:06:19

moleculin-biotech-may-sell-shares-up-to-65m
Moleculin Biotech May Sell Shares Up To $6.5M
07/11/2025 21:30:52

-SEC Filing

moleculin-biotech-secures-georgian-regulation-agency-for-medical-and-pharmaceutical-activities-approval-for-phase-2b3-miracle-aml-trial-european-medicines-agency-boosts-profile-as-enrollment-expands-to-30-sites-with-data-readout-expected-in-2h-2025
Moleculin Biotech Secures Georgian Regulat...
07/09/2025 12:37:02

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION